Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
复制标题
DOI：
10.1002/mds.22307
复制
发表时间：
2009-01-30
影响因子：
8.6
通讯作者：
Williams, James R.
中科院分区：
文献类型：
--
作者：
Marsh, Laura;Biglan, Kevin;Gerstenhaber, Melissa;Williams, James R.
执行功能障碍（艾德）是帕金森病（PD）认知功能障碍的一个突出且经常致残的特征。很少有研究检查治疗方法。鉴于去甲肾上腺素能病理学在艾德中的作用，托莫西汀（一种适用于注意缺陷多动障碍（ADHD）的去甲肾上腺素再摄取抑制剂）可能是PD相关ED的潜在治疗方法。12例PD和致残性艾德患者完成了一项为期8周的托莫西汀开放标签、灵活剂量（25 - 100 mg/天）初探性试验。在主要结局指标方面，托莫西汀与基于临床总体印象变化量表（75%阳性应答率; 95% CI：43%-95%，p<.05）和艾德行为指标[额叶系统行为量表（FrSBE）执行功能障碍和Connors成人ADHD评定量表（CAARS）注意力/记忆力子量表]的艾德改善相关。不良反应包括睡眠、胃肠道紊乱和轻躁狂。托莫西汀在PD患者中是耐受的，可能有益于艾德的临床表现，值得在对照试验中进一步研究。
Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson’s disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. 12 patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25 to 100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43%-95%, p<.05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.
登录
查看更多内容
影响因子：
11
作者：
HUGHES, AJ;DANIEL, SE;LEES, AJ
通讯作者：
LEES, AJ
影响因子：
3.3
作者：
Brusa, L;Bassi, A;Stanzione, P
通讯作者：
Stanzione, P
影响因子：
3.4
作者：
Riekkinen, M;Kejonen, K;Riekkinen, P
通讯作者：
Riekkinen, P
影响因子：
10.6
作者：
Michelson, D;Adler, L;Milton, D
通讯作者：
Milton, D
DOI：
10.1111/j.1600-0447.1987.tb10566.x
发表时间：
1987-01-01
期刊：
Acta Psychiatrica Scandinavica Supplementum
影响因子：
--
作者：
LINGJAERDE O;AHLFORS U G;ELGEN K
通讯作者：
ELGEN K